A recent study conducted by Steven Greenstein evaluated the long-term effects of Epi-off corneal collagen cross-linking (CXL) treatment. This therapy was first FDA approved in 2016. It is a therapy…
A recent study has pointed to corneal collagen crosslinking (CXL) as a viable treatment option for children with keratoconus, a rare ocular disorder that impacts the cornea. As pediatric patients…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
